Every material Form 8-K Latigo Biotherapeutics, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Latigo Biotherapeutics reported a third-quarter 2026 net loss of $20.9 million, down from $24.8 million a year earlier, and cash of $401.2 million that the company expects will fund operations into 2029. The company also said Todd Smith became president and CEO effective November 3, 2026, replacing Nima Farzan, who also resigned from the board.
Q3 2026 net loss was $20.9 million, versus $24.8 million in Q3 2025; R&D expenses fell to $17.5 million from $22.1 million, while G&A rose to $5.4 million from $2.6 million.
Cash and cash equivalents were $401.2 million as of September 30, 2026, expected to fund current operating plans into 2029.
Todd Smith became CEO effective November 3, 2026, with a $775,000 base salary, a 70% target cash incentive, and an option award with a $20 million grant-date fair value.
Nima Farzan will remain an employee through January 1, 2027, receive his 2026 bonus at 100% of target, and then serve as a consultant through December 31, 2027.
Latigo Biotherapeutics reported a second-quarter 2026 net loss of $25.8 million, unchanged from the same quarter of 2025, as lower research and development expenses offset higher general and administrative costs. The company said it completed an upsized initial public offering in August 2026 with gross proceeds of $397.4 million, and that cash and the IPO proceeds are projected to fund operations into 2029.
Net loss was $25.8 million for the three months ended June 30, 2026, and for the same period in 2025.
Research and development expenses fell to $21.2 million from $22.9 million; general and administrative expenses rose to $4.6 million from $2.8 million.
IPO completed in August 2026 with gross proceeds of $397.4 million, before underwriting discounts, commissions and other offering expenses.
Cash and cash equivalents were $55.0 million as of June 30, 2026, before the IPO proceeds.
Latigo Biotherapeutics, Inc. closed its initial public offering on August 10, 2026, selling 19,200,000 shares of common stock at $18.00 per share. Gross proceeds were approximately $345.6 million before underwriting discounts, commissions and offering expenses. The company also filed an amended and restated certificate of incorporation and adopted amended and restated bylaws in connection with the closing.
IPO: 19,200,000 common shares sold at $18.00 per share on August 10, 2026
Gross proceeds of approximately $345.6 million, before underwriting discounts and expenses
Restated certificate of incorporation filed with the Delaware Secretary of State and restated bylaws adopted, both effective August 10, 2026
Full text of the restated documents filed as Exhibits 3.1 and 3.2
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Latigo Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →